Merck’s MRK stock has risen 30.4% this year so far compared with an increase of 4.3% for the industry. An ongoing recovery from the disruptions related to the pandemic and strong global underlying ...

Merck MRK boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.

Vree TM for Diabetes 2.0 Helps Patients Manage Their Condition and Facilitates Communication with Healthcare Providers Merck today announced the launch of a mobile application designed to be used by ...

A new partnership aimed at bringing long-acting HIV treatments to market has been announced by Gilead Sciences and Merck. The two pharmaceutical firms have entered into an agreement to co-develop and ...

Improving patients’ beliefs about their medication therapies may significantly improve medication adherence, according to a set of studies sponsored by drug maker Merck and presented last month at the ...